Thus, a screening test that will include the ERCC1 (rs3212986), ERCC2 (rs13181), XRCC1 (rs25487), and XRCC3 (rs861539) genes may well be helpful for the prevention and earliest treatment of patients with glioma susceptibility. This evidence concerns the gene ERCC2 and central nervous system cancer.